Phaseline

Companies › Panbela Therapeutics

Panbela Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SBP-101 (ivospemin)
Polyamine metabolic inhibitor
–Phase 2Pancreatic Cancer MetastaticJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05254171SBP-101 (ivospemin)Phase 2Pancreatic Cancer MetastaticOncologyJan 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Apollomics Elevar Therapeutics Zenith Epigenetics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.